Paszat Lawrence, Sutradhar Rinku, Luo Jin, Rabeneck Linda, Tinmouth Jill, Baxter Nancy N
Institute for Healthcare Policy, Management, and Evaluation, University of Toronto, Toronto, Ontario, Canada.
Cancer Research Program, ICES, Toronto, Ontario, Canada.
J Can Assoc Gastroenterol. 2021 Mar 6;4(6):274-283. doi: 10.1093/jcag/gwab001. eCollection 2021 Dec.
The cost-effectiveness of colorectal screening has been modeled; however, the cost of health care following the diagnosis of colorectal cancer has not been described stratified by history of colorectal evaluative procedures.
We identified persons with first diagnosis of colorectal cancer between 2015 and 2017 from the Ontario Cancer Registry, and categorized them by history of colorectal evaluative procedures during Period 1 (the 10 years before the 6-month prediagnostic interval) with or without procedures during Period 2 (the 6 month prediagnostic interval), versus only during Period 2, versus none. We extracted overall health care cost 1 year following diagnosis from population-wide administrative databases.
Among cases diagnosed at 52 to 74 years, overall health care cost among those with no colorectal evaluative procedures on or before the date of diagnosis is $71,039.65 (SD $51,825.18), compared to $48,406.15 (SD $38,843.64) among those who received colorectal evaluative procedures during Period 1, with or without procedures during Period 2. Among the population aged 20 to 74 years at diagnosis, cases with ≥1 screening colonoscopies for hereditary CRC syndrome, the mean overall initial cost was between $32,300.32 (SD) and $33,084.67 (SD $39,905.77), and those with ≥1 screening colonoscopies because of a first-degree relative with CRC, was between $36,344.71 (SD $35,539.85) and $45,456.41 (SD $49,818.59).
Overall health care cost is lower among cases who received colorectal evaluative procedures during Period 1, with or without procedures during Period 2, and among those with screening colonoscopy for hereditary CRC syndromes or affected first-degree relatives.
已对结直肠癌筛查的成本效益进行了建模;然而,结直肠癌诊断后的医疗保健成本尚未按结直肠评估程序的历史进行分层描述。
我们从安大略癌症登记处确定了2015年至2017年首次诊断为结直肠癌的患者,并根据第1阶段(诊断前6个月间隔期前的10年)的结直肠评估程序历史进行分类,第2阶段(诊断前6个月间隔期)有无相关程序,与仅在第2阶段有程序,或无程序的情况进行对比。我们从全人群行政数据库中提取诊断后1年的总体医疗保健成本。
在52至74岁诊断出的病例中,诊断日期当日或之前未进行结直肠评估程序的患者,总体医疗保健成本为71,039.65美元(标准差51,825.18美元),而在第1阶段接受了结直肠评估程序(无论第2阶段有无程序)的患者中,这一成本为48,406.15美元(标准差38,843.64美元)。在诊断时年龄为20至74岁的人群中,因遗传性结直肠癌综合征进行过≥1次筛查结肠镜检查的病例,平均总体初始成本在32,300.32美元(标准差)至33,084.67美元(标准差39,905.77美元)之间,因有结直肠癌的一级亲属而进行过≥1次筛查结肠镜检查的病例,成本在36,344.71美元(标准差35,539.85美元)至45,456.41美元(标准差49,818.59美元)之间。
在第1阶段接受了结直肠评估程序(无论第2阶段有无程序)的病例中,以及在因遗传性结直肠癌综合征或受影响的一级亲属而进行筛查结肠镜检查的病例中,总体医疗保健成本较低。